{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:06:56Z","timestamp":1788336416863,"version":"build-2803163510"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0059390","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T21:04:31Z","timestamp":1363727071000},"page":"e59390","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["cMyc\/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas"],"prefix":"10.1371","volume":"8","author":[{"given":"Valentina","family":"Manf\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Biskup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalah","family":"Willumsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Guldhammer","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lagan\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Woetmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"\u00d8dum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/10428190310001639489","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin&apos;s lymphoma","volume":"45","author":"L Hendry","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"D Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin&apos;s lymphoma","volume":"23","author":"A Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin&apos;s lymphoma and mantle cell lymphoma","volume":"23","author":"OA O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","article-title":"Many facets of bortezomib resistance\/susceptibility","volume":"112","author":"S Kumar","year":"2008","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/ajh.22139","article-title":"Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"RA Wilcox","year":"2011","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"R Willemze","year":"2005","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"PL Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach","volume":"6","author":"SM Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.3816\/CLM.2008.s.015","article-title":"Novel therapies for cutaneous T-cell lymphomas","volume":"8","author":"SM Horwitz","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"19488","DOI":"10.1073\/pnas.0708380104","article-title":"Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition","volume":"104","author":"MA Nikiforov","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood-2007-12-130823","article-title":"Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA","volume":"112","author":"ST Nawrocki","year":"2008","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1755-148X.2007.00438.x","article-title":"MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect","volume":"21","author":"SY Fuchs","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/0008-5472.CAN-07-6398","article-title":"Novel and highly recurrent chromosomal alterations in Sezary syndrome","volume":"68","author":"MH Vermeer","year":"2008","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0344-0338(11)80423-1","article-title":"Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus","volume":"190","author":"P Kanavaros","year":"1994","journal-title":"Pathol Res Pract"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"MV Iorio","year":"2012","journal-title":"EMBO Mol Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1200\/JCO.2009.24.0317","article-title":"MicroRNAs in cancer: small molecules with a huge impact","volume":"27","author":"MV Iorio","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.leukres.2005.10.017","article-title":"MicroRNAs and leukemias: how strong is the connection?","volume":"30","author":"GA Calin","year":"2006","journal-title":"Leuk Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.joca.2012.02.010","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"20","author":"C Kilkenny","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.154.5.1403","article-title":"Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor","volume":"154","author":"JE Gootenberg","year":"1981","journal-title":"J Exp Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00431220","article-title":"A continuous T-cell line from a patient with Sezary syndrome","volume":"279","author":"K Kaltoft","year":"1987","journal-title":"Arch Dermatol Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e29541","DOI":"10.1371\/journal.pone.0029541","article-title":"miR-122 regulates p53\/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma","volume":"7","author":"V Manfe","year":"2012","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Schug J (2008) Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics Chapter 2: Unit.","DOI":"10.1002\/0471250953.bi0206s21"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/nsmb.2115","article-title":"Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs","volume":"18","author":"DM Garcia","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"A Krek","year":"2005","journal-title":"Nat Genet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djq102","article-title":"MicroRNA cluster 221\u2013222 and estrogen receptor alpha interactions in breast cancer","volume":"102","author":"LG Di","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Biskup E, Kamstrup M, Manfe V, Gniadecki R (2012) Proteasome inhibition as a novel mechanism of the proapoptotic activity of g-secretase blocker I (GSI I) in cutaneous T-cell lymphoma. Br J Dermatol.","DOI":"10.1111\/bjd.12071"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"TC Chang","year":"2008","journal-title":"Nat Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1073\/pnas.0808300106","article-title":"Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation","volume":"106","author":"TC Chang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17\u201392 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"L Venturini","year":"2007","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/onc.2009.429","article-title":"MYCN\/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN\/c-MYC-activated tumors","volume":"29","author":"P Mestdagh","year":"2010","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"c-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"KA O'Donnell","year":"2005","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Onnis A, De FG, Antonicelli G, Onorati M, Bellan C, <etal>et al<\/etal>.. (2010) Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 5.","DOI":"10.1371\/journal.pone.0012960"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1158\/0008-5472.CAN-07-2462","article-title":"MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells","volume":"67","author":"VB Sampson","year":"2007","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/nat.2012.0343","article-title":"The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation","volume":"22","author":"M Rizzo","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.biocel.2010.03.004","article-title":"mir-17\u201392, a cluster of miRNAs in the midst of the cancer network","volume":"42","author":"V Olive","year":"2010","journal-title":"Int J Biochem Cell Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/path.2958","article-title":"MiR-17\/106b seed family regulates p21 in Hodgkin&apos;s lymphoma","volume":"225","author":"JH Gibcus","year":"2011","journal-title":"J Pathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/labinvest.2012.129","article-title":"The miR-17\u201392 microRNA cluster: a novel diagnostic tool in large B-cell malignancies","volume":"92","author":"A Fassina","year":"2012","journal-title":"Lab Invest"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1182\/blood-2010-10-312231","article-title":"Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1","volume":"117","author":"VJ Craig","year":"2011","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/carcin\/bgq033","article-title":"Epigenetic inactivation of the miR-34a in hematological malignancies","volume":"31","author":"CS Chim","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1600-0625.2010.01138.x","article-title":"A novel xenograft model of cutaneous T-cell lymphoma","volume":"19","author":"T Krejsgaard","year":"2010","journal-title":"Exp Dermatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/leu.2012.90","article-title":"MiR-125 in normal and malignant hematopoiesis","volume":"26","author":"L Shaham","year":"2012","journal-title":"Leukemia"},{"key":"ref44","first-page":"1362","article-title":"Leukemia","volume":"24","author":"E Chapiro","year":"2010"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1084\/jem.20080285","article-title":"Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation","volume":"205","author":"M Bousquet","year":"2008","journal-title":"J Exp Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/intimm\/dxq042","article-title":"MicroRNA 125b inhibition of B cell differentiation in germinal centers","volume":"22","author":"M Gururajan","year":"2010","journal-title":"Int Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3324\/haematol.2010.026138","article-title":"MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia","volume":"96","author":"D Schotte","year":"2011","journal-title":"Haematologica"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"21505","DOI":"10.1073\/pnas.1016218107","article-title":"MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets","volume":"107","author":"AG Ooi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/j.1460-2075.1996.tb00555.x","article-title":"Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation","volume":"15","author":"PJ Hurlin","year":"1996","journal-title":"EMBO J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6600065","article-title":"Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression","volume":"86","author":"I Manni","year":"2002","journal-title":"Br J Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e38508","DOI":"10.1371\/journal.pone.0038508","article-title":"Role of MXD3 in proliferation of DAOY human medulloblastoma cells","volume":"7","author":"GA Barisone","year":"2012","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1080\/10428190701342018","article-title":"Expression and mutation analysis of genes that encode the Myc antagonists Mad1, Mxi1 and Rox in acute leukaemia","volume":"48","author":"XL Guo","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1073\/pnas.162369299","article-title":"Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo","volume":"99","author":"L James","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/35070076","article-title":"Repression of p15INK4b expression by Myc through association with Miz-1","volume":"3","author":"P Staller","year":"2001","journal-title":"Nat Cell Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","article-title":"The Myc\/Max\/Mad network and the transcriptional control of cell behavior","volume":"16","author":"C Grandori","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"N Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc904","article-title":"c-MYC: more than just a matter of life and death","volume":"2","author":"S Pelengaris","year":"2002","journal-title":"Nat Rev Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0059390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T04:06:49Z","timestamp":1562818009000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0059390"}},"subtitle":[],"editor":[{"given":"Maria G.","family":"Masucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,19]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0059390","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,19]]}}}